(5R)-5-Hydroxytriptolide for NF-κB-Mediated Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no effective drugs available for the treatment or prevention of abnormal immune activation and incomplete immune reconstitution associated with AIDS, which are significant contributors to the progression and complications of the disease.
Innovation Solution
Utilizing (5R)-5-hydroxytriptolide to inhibit NF-κB activity and CD4+ T-cell activation, thereby addressing abnormal immune activation and incomplete immune reconstitution in AIDS patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If triptolide is used for immunosuppression in AIDS, then immunosuppressive activity is improved, but toxicity and side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of triptolide at position 5 to create (5R)-5-hydroxytriptolide. This structural modification changes the pharmacological parameters of the compound, maintaining immunosuppressive activity while reducing toxicity and side effects, thereby resolving the contradiction between therapeutic efficacy and safety
2Reliability
If no specific medicament is used for abnormal immune activation in AIDS, then existing antiviral therapy continues, but immune reconstitution remains incomplete and mortality rate increases
Solution Approach 1:
The patent extracts and addresses the specific problem of abnormal immune activation as a separate treatable condition from HIV viral replication itself. By identifying NF-κB pathway inhibition as the specific mechanism to address immune activation, the patent enables targeted treatment of this previously unaddressed aspect of AIDS pathology, improving immune reconstitution and reducing mortality
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed in the present invention is an application of (5R)-5-hydroxytriptolide in the preparation of drugs, in particular an application in the preparation of drugs for treating and/or preventing acquired immune deficiency syndrome (AIDS) abnormal immune activation or incomplete immune reconstitution associated with AIDS abnormal immune activation. The present invention uses (5R)-5-hydroxytriptolide (T8) in experiments and finds that (5R)-5-hydroxytriptolide has an immunosuppressive activity against AIDS abnormal immune activation or incomplete immune reconstitution associated with AIDS abnormal immune activation, is characterized by high efficiency and low toxicity, and has a good safety treatment index.